Forum Financial Management LP Raises Stake in Johnson & Johnson (NYSE:JNJ)

Forum Financial Management LP grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 31.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 32,409 shares of the company's stock after buying an additional 7,826 shares during the quarter. Forum Financial Management LP's holdings in Johnson & Johnson were worth $4,687,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. MRP Capital Investments LLC raised its stake in Johnson & Johnson by 4.1% during the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after buying an additional 65 shares during the period. Syverson Strege & Co lifted its position in Johnson & Johnson by 4.9% during the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after acquiring an additional 65 shares during the last quarter. Werba Rubin Papier Wealth Management grew its position in shares of Johnson & Johnson by 3.3% during the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after purchasing an additional 66 shares in the last quarter. Denali Advisors LLC grew its stake in Johnson & Johnson by 1.3% during the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock worth $742,000 after buying an additional 67 shares in the last quarter. Finally, Sage Mountain Advisors LLC boosted its stake in Johnson & Johnson by 0.5% in the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock valued at $2,106,000 after buying an additional 67 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Raymond James dropped their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Royal Bank of Canada restated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Morgan Stanley upped their target price on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 16th. Finally, Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $0.71 during trading hours on Wednesday, hitting $152.54. The company's stock had a trading volume of 2,573,172 shares, compared to its average volume of 7,940,292. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The business has a 50 day moving average price of $154.85 and a two-hundred day moving average price of $153.65. The company has a market cap of $367.01 billion, a PE ratio of 22.94, a PEG ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.41%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.